Drugs / AB-101
AB-101
Trials 7 · a red edge is where a trial was stopped
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05960240 ↗ |
| Known as | AlloNK | “AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells.” NCT06265220 ↗ |
| Known as | Insular | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297681 ↗ |
| Known as | zabalafin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06855745 ↗ |
| Action | Inhibit | “PD-L1 checkpoint inhibitor” NCT05960240 ↗ |
| Modality | Cell therapy | “AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells.” NCT04673617 ↗ |
| Route | Intravenous | “NK cell therapy, intravenous infusion” NCT05883449 ↗ |